ARVNArvinasARVN info
$18.48info3.65%24h
Global rank7895
Market cap$1.02B
Change 7d-5.42%
YTD Performance-54.66%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Arvinas (ARVN) Stock Overview

    Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

    ARVN Stock Information

    Symbol
    ARVN
    Address
    5 Science ParkNew Haven, CT 06511United States
    Founded
    -
    Trading hours
    9:30 AM - 4:00 PM ET
    Website
    https://www.arvinas.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    203 535 1456

    Arvinas (ARVN) Price Chart

    -
    Value:-

    Arvinas Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $18.48
    N/A
    Market Cap
    $1.02B
    N/A
    Shares Outstanding
    55.03M
    N/A
    Employees
    415.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org